BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 25245924)

  • 1. Molecular genetics of meningiomas: Building the roadmap towards personalized therapy.
    Peyre M; Kalamarides M
    Neurochirurgie; 2018 Mar; 64(1):22-28. PubMed ID: 25245924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
    Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV
    BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meningioma: current updates on genetics, classification, and mouse modeling.
    Szulzewsky F; Thirimanne HN; Holland EC
    Ups J Med Sci; 2024; 129():. PubMed ID: 38571886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.
    Abedalthagafi M; Bi WL; Aizer AA; Merrill PH; Brewster R; Agarwalla PK; Listewnik ML; Dias-Santagata D; Thorner AR; Van Hummelen P; Brastianos PK; Reardon DA; Wen PY; Al-Mefty O; Ramkissoon SH; Folkerth RD; Ligon KL; Ligon AH; Alexander BM; Dunn IF; Beroukhim R; Santagata S
    Neuro Oncol; 2016 May; 18(5):649-55. PubMed ID: 26826201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.
    Zhang X; Jia H; Lu Y; Dong C; Hou J; Wang Z; Wang F; Zhong H; Wang L; Wang K
    Discov Med; 2014 Dec; 18(101):301-311. PubMed ID: 25549701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new amplicon-based gene panel for next generation sequencing characterization of meningiomas.
    Mawrin C; Koch R; Waldt N; Sandalcioglu IE; Braunsdorf WEK; Warnke JP; Goehre F; Meisel HJ; Ewald C; Neyazi S; Schüller U; Kirches E
    Brain Pathol; 2022 Mar; 32(2):e13046. PubMed ID: 35213080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic landscape of meningioma.
    Yuzawa S; Nishihara H; Tanaka S
    Brain Tumor Pathol; 2016 Oct; 33(4):237-247. PubMed ID: 27624470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.
    Clark VE; Erson-Omay EZ; Serin A; Yin J; Cotney J; Ozduman K; Avşar T; Li J; Murray PB; Henegariu O; Yilmaz S; Günel JM; Carrión-Grant G; Yilmaz B; Grady C; Tanrikulu B; Bakircioğlu M; Kaymakçalan H; Caglayan AO; Sencar L; Ceyhun E; Atik AF; Bayri Y; Bai H; Kolb LE; Hebert RM; Omay SB; Mishra-Gorur K; Choi M; Overton JD; Holland EC; Mane S; State MW; Bilgüvar K; Baehring JM; Gutin PH; Piepmeier JM; Vortmeyer A; Brennan CW; Pamir MN; Kiliç T; Lifton RP; Noonan JP; Yasuno K; Günel M
    Science; 2013 Mar; 339(6123):1077-80. PubMed ID: 23348505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular alterations in meningioma: prognostic and therapeutic perspectives.
    Birzu C; Peyre M; Sahm F
    Curr Opin Oncol; 2020 Nov; 32(6):613-622. PubMed ID: 32890025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic radiation for childhood cancer drives structural aberrations of NF2 in meningiomas.
    Agnihotri S; Suppiah S; Tonge PD; Jalali S; Danesh A; Bruce JP; Mamatjan Y; Klironomos G; Gonen L; Au K; Mansouri S; Karimi S; Sahm F; von Deimling A; Taylor MD; Laperriere NJ; Pugh TJ; Aldape KD; Zadeh G
    Nat Commun; 2017 Aug; 8(1):186. PubMed ID: 28775249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT.
    Jungwirth G; Warta R; Beynon C; Sahm F; von Deimling A; Unterberg A; Herold-Mende C; Jungk C
    Acta Neuropathol Commun; 2019 Aug; 7(1):140. PubMed ID: 31470906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations.
    Reuss DE; Piro RM; Jones DT; Simon M; Ketter R; Kool M; Becker A; Sahm F; Pusch S; Meyer J; Hagenlocher C; Schweizer L; Capper D; Kickingereder P; Mucha J; Koelsche C; Jäger N; Santarius T; Tarpey PS; Stephens PJ; Andrew Futreal P; Wellenreuther R; Kraus J; Lenartz D; Herold-Mende C; Hartmann C; Mawrin C; Giese N; Eils R; Collins VP; König R; Wiestler OD; Pfister SM; von Deimling A
    Acta Neuropathol; 2013 Mar; 125(3):351-8. PubMed ID: 23404370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic Landscape of Meningiomas.
    Wang JZ; Nassiri F; Mawrin C; Zadeh G
    Adv Exp Med Biol; 2023; 1416():137-158. PubMed ID: 37432625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas.
    Hao S; Huang G; Feng J; Li D; Wang K; Wang L; Wu Z; Wan H; Zhang L; Zhang J
    J Neurooncol; 2019 Aug; 144(1):11-20. PubMed ID: 31177425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical impact of targeted amplicon sequencing for meningioma as a practical clinical-sequencing system.
    Yuzawa S; Nishihara H; Yamaguchi S; Mohri H; Wang L; Kimura T; Tsuda M; Tanino M; Kobayashi H; Terasaka S; Houkin K; Sato N; Tanaka S
    Mod Pathol; 2016 Jul; 29(7):708-16. PubMed ID: 27102344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meningioma genomics: a therapeutic challenge for clinicians.
    Moussalem C; Massaad E; Minassian GB; Ftouni L; Bsat S; Houshiemy MNE; Alomari S; Sarieddine R; Kobeissy F; Omeis I
    J Integr Neurosci; 2021 Jun; 20(2):463-469. PubMed ID: 34258948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular alterations in meningiomas: Literature review.
    Pereira BJA; Oba-Shinjo SM; de Almeida AN; Marie SKN
    Clin Neurol Neurosurg; 2019 Jan; 176():89-96. PubMed ID: 30553171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The molecular genetics of meningiomas and genotypic/phenotypic correlations].
    Dezamis E; Sanson M
    Rev Neurol (Paris); 2003 Sep; 159(8-9):727-38. PubMed ID: 13679715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of genetic alterations and methylation classes in meningioma.
    Berghoff AS; Hielscher T; Ricken G; Furtner J; Schrimpf D; Widhalm G; Rajky U; Marosi C; Hainfellner JA; von Deimling A; Sahm F; Preusser M
    Brain Pathol; 2022 Mar; 32(2):e12970. PubMed ID: 35213082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Meningioma].
    Sasaki H
    No Shinkei Geka; 2023 Sep; 51(5):829-836. PubMed ID: 37743334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.